Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
Commentary|Videos|November 22, 2024
Dr Elder on the Initial Safety Profile of IGV-001 in Newly Diagnosed Glioblastoma
Author(s)J. Bradley Elder, MD
J. Bradley Elder, MD, discusses blinded early-safety data from a phase 2b trial of IGV-001 in patients with newly diagnosed glioblastoma.
Advertisement
J. Bradley Elder, MD, director, Neurosurgical Oncology; professor, Department of Neurological Surgery, the Brain and Spine Tumor Center, The Ohio State University Wexner Medical Center, discusses
Advertisement
Related to this article
Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
Peter E. Fecci, MD, PhD, discusses unmet needs in glioblastoma management and the early promise of CAR T-cell therapy in this disease.
Early phase 2 data showed a median OS of 29.3 months with BPM31510 plus chemoradiation in an MGMT-unmethylated subgroup of treatment-naive glioblastoma.
The TRIPP-FFX trial met its primary end points of local disease control and safety with P-32 microparticles plus FOLFIRINOX pancreatic adenocarcinoma.
Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.
Phase 1/2 data from 2 trials showed high ORRs with zoldonrasib-based regimens in first-line and previously treated RAS G12D metastatic pancreatic ductal adenocarcinoma.
In a phase 3 trial analysis, DCVax-L extended OS compared with individual patient data from external control populations in patients with glioblastoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
2
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
3
Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC
4
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
5